Sulphonamides Market Size - By Route of Administration (Oral, Topical), Application (Skin Infection, GIT, UTI, RTI), Medication Type (Generics, Branded), Distribution Channel (Hospital, Retail, & Online Pharmacies), & Global Forecast, 2024 – 2032

Sulphonamides Market Size - By Route of Administration (Oral, Topical), Application (Skin Infection, GIT, UTI, RTI), Medication Type (Generics, Branded), Distribution Channel (Hospital, Retail, & Online Pharmacies), & Global Forecast, 2024 – 2032

Sulphonamides Market Size

Sulphonamides Market was valued at USD 122.4 million in 2023 and is estimated to grow at 4.8% CAGR from 2024 to 2032, driven by the increasing prevalence of infectious diseases globally. Furthermore, the increasing awareness among healthcare providers and patients about the effectiveness of sulphonamides is contributing to their higher prescription rates, thereby further expanding the market growth.

To get key market trends

  Download Free Sample

Sulphonamide treatment involves the use of medications from the sulphonamide group, which are synthetic antimicrobial agents. These drugs inhibit the growth and multiplication of bacteria by acting as competitive inhibitors of the enzyme dihydropteroate synthase involved in folate synthesis. Sulphonamides are bacteriostatic, meaning they inhibit bacterial growth without killing the bacteria. They are commonly used to treat bacterial infections, UTIs, and other conditions.

What are the growth opportunities in this market?

 Download Free Sample

Sulphonamides Market Trends

The elevated cases of bacterial infections, including hospital-acquired infections (HAIs), resulted in an ongoing need for effective antibiotics to address and resolve these diseases, thereby driving up the demand for sulphonamides. HAIs, often caused by resistant bacteria, pose significant health risks and complications for patients. Sulphonamides, known for their broad-spectrum antibacterial properties, are frequently used to combat these infections bolstering the market demand.

• For instance, the NHS and UK Health Security Agency (UKHSA) are highlighting the prevalence of UTIs, with recent data revealing over 800,000 hospital admissions in the past five years. Between 2018-19 and 2022-23, there were over 1.8 million admissions, predominantly among individuals aged 65 and above. Thus, the ongoing occurrence of HAIs ensured a persistent demand for effective antibiotics including sulphonamides, striving to reduce infection rates and improve patient outcomes.

Moreover, advancing healthcare infrastructure, antibiotic resistance, raising awareness campaigns, and intensified research and development activities further accelerate the demand for sulphonamides in the market.

Sulphonamides Market Analysis

Learn more about the key segments shaping this market

 Download Free Sample

Based on the route of administration, the market is categorized into oral, topical, and other routes of administration. The oral segment was worth over USD 66.2 million in 2023 and is projected to reach USD 98.6 million by 2032.

• Oral formulations offer convenient administration, facilitating patient compliance and ensuring timely treatment initiation. This effectiveness makes oral sulphonamides a preferred choice for both healthcare providers and patients in managing a variety of bacterial infections.
• Additionally, their ease of use contributes to broader accessibility and adoption, further bolstering market demand for oral sulphonamides

Learn more about the key segments shaping this market

 Download Free Sample

Based on application, the sulphonamides market is classified into skin infection, gastrointestinal (GIT) infection, urinary tract infection (UTI), respiratory tract infection (RTI), and other applications. The skin infection segment holds the largest market share of 27.7% in 2023.

• The high segmental revenue is due to the rising prevalence of various skin conditions such as acne, dermatitis, and bacterial skin infections. Sulphonamides offer effective antibacterial properties, making them a preferred choice for treating a wide range of skin infections.
• For instance, The National Center for Biotechnology Information (NCBI) reports that cellulitis, a common bacterial skin infection, accounts for over 14 million cases annually in the U.S. This prevalent condition leads to approximately 650,000 hospital admissions per year and incurs ambulatory care expenses of around $3.7 billion. Therefore, as the burden of cellulitis and other skin infections continues to increase, the demand for potent sulphonamide therapeutics is anticipated to rise correspondingly, propelling the segment growth.

Based on medication type, the market is segmented into branded and generics. In 2023, the branded segment asserted its dominance in the market, capturing the largest share of revenue, fuelled by a robust CAGR of 4.7% through 2032.

• The branded segment has asserted dominance in the sulphonamides market owing to established brand recognition, trust among healthcare providers, and perceived higher quality compared to generic alternatives.
• Branded sulphonamide products often undergo extensive research, development, and marketing efforts, resulting in higher pricing but also perceived efficacy and safety.
• Healthcare professionals and patients often prefer branded formulations due to their perceived reliability and consistent quality standards, consolidating the branded segment's leadership in the market.

Based on the distribution channel, the sulphonamides market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the largest market revenue in 2023.

• Hospital pharmacies typically have a higher demand for sulphonamide drugs as they often stock a wide range of medications, including branded and generic sulphonamides, to cater to the diverse needs of patients admitted for various medical conditions, thereby consolidating their dominance in this market.
• Further, pharmacists in hospitals collaborate closely with healthcare teams to provide personalized medication therapy management, ensuring optimal therapeutic outcomes. Such benefits associated with hospital pharmacies will spur the segmental growth.

Looking for region specific data?

 Download Free Sample

The U.S. dominated the North American sulphonamides market accounting for USD 48 million in 2023 and is anticipated to show significant growth.

• The country level market growth is due to high prevalence and incidence of infectious diseases. For instance, according to a CDC article from November 2021, millions of Americans are affected by the common cold annually, with adults experiencing it 2-3 times per year on average, and children being particularly susceptible.
• Consequently, the country characterized by leading pharmaceutical industry with extensive research and development activities, leading to the introduction of innovative sulphonamide formulations and combination therapies, has solidified its position, anticipating retaining a significant share in the North American market.

Germany exhibited a high growth potential in the European sulphonamides market.

• The country's emphasis on preventive care, early diagnosis, and comprehensive treatment contributes to the significant demand for sulphonamide medications.
• Germany boasts a large network of pharmacies, hospitals, and healthcare facilities, ensuring accessibility to sulphonamide treatments across the population.
• Additionally, Germany's strong regulatory framework ensures the quality, safety, and efficacy of sulphonamide products available in the market, further reinforcing its prominence in the European sulphonamide market.

The Asia Pacific sulphonamides market is poised witness 5.3% CAGR up to 2032.

• The Asia Pacific region presented a significant growth opportunity in the sulphonamides industry due to the rapidly growing population, leading to a high burden of infectious diseases such as respiratory infections, gastrointestinal infections, and sexually transmitted infections, driving the demand for sulphonamide drugs in the region.
• Moreover, improving healthcare infrastructure, rising healthcare expenditure, and expanding access to healthcare services in countries like China, India, and Japan are contributing to the growth of the sulphonamide market in the region.
• Furthermore, increasing government initiatives aimed at improving healthcare access and affordability, along with regulatory reforms to enhance drug safety and efficacy, are expected to further propel the growth of the sulphonamide market in the Asia Pacific region.

Sulphonamides Market Share

The competitive landscape of the sulphonamides industry is characterized by the presence of key players focused on innovation, research, and strategic partnerships. Also, the market witnessed competition from generic drug manufacturers offering cost-effective alternatives. The collaboration and licensing agreements between pharmaceutical companies and academic institutions further intensify competition, driving advancements and market growth in the sulphonamides sector.

Sulphonamides Market Companies

Some of the prominent players operating in the sulphonamides industry include

• Allergan
• Amneal Pharmaceuticals LLC
• Aurobindo Pharma
• Bausch & Lomb Incorporated
• Cadila Pharmaceuticals Ltd.
• Cipla Ltd.
• Dr. Reddy’s Laboratories
• F. Hoffmann-La Roche Ltd.
• GSK PLC
• Glenmark Pharma Ltd.
• Lexine Technochem Pvt. Ltd.
• Monarch Pharmaceuticals
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

Sulphonamides Industry News

• In February 2024, Cipla received approval from the Central Drugs Standard Control Organization (CDSCO) to market plazomicin (plazomicin sulfate), an antibiotic, in India. This approval allows for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis (kidney infection). This strategy is expected to add value to its existing business portfolio.
• In February 2023, Travere Therapeutics, Inc. has received accelerated approval from the U.S. Food and Drug Administration (FDA) for FILSPARI (sparsentan). This approval for reducing proteinuria in adults with primary IgA nephropathy (IgAN) is at risk of rapid disease progression, typically indicated by a high urine protein-to-creatinine ratio. The strategy enabled company to expand its product offerings and generate revenue from its sales.

This sulphonamides market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments

Click here to Buy Section of this Report

Market, By Route of Administration

• Oral
• Topical
• Other routes of administration

Market, By Application

• Skin infection
• Gastrointestinal (GIT) infection
• Urinary tract infection (UTI)
• Respiratory tract infection (RTI)
• Other applications

Market, By Medication Type

• Branded
• Generics

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa